Use of biologics for the management of Crohn's disease: IG-IBD technical review based on the GRADE methodology

Stefanos Bonovas,Daniele Piovani,Claudia Pansieri,Fabio Salvatore Macaluso,Ambrogio Orlando,Stefano Festa,Claudio Papi,Daniela Pugliese,Alessandro Armuzzi

Digestive and Liver Disease（2023）

引用 0|浏览3

暂无评分

摘要

The therapeutic armamentarium for the management of Crohn's disease (CD) is rapidly expanding. Several biologic therapies (e.g. infliximab, adalimumab, vedolizumab, and ustekinumab) have been regulatory approved, and there is considerable practice variability in the treatment of patients with CD.

查看译文

关键词

Crohn's disease,GRADE,Guidelines

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要